Literature DB >> 1691226

Analysis of the site in CD4 that binds to the HIV envelope glycoprotein.

M H Brodsky1, M Warton, R M Myers, D R Littman.   

Abstract

The first step in infection of human mononuclear cells with HIV involves the high affinity binding of the viral envelope glycoprotein, gp120, to the cell-surface receptor, CD4. To gain a better understanding of the molecular basis of this interaction, we have analyzed the ability of gp120 to bind to a panel of 40 mutant CD4 proteins containing single or double amino acid substitutions. In addition, the binding of several anti-CD4 mAb to the mutant CD4 proteins was measured. These mAb were chosen on the basis of the previous demonstration that they bind to epitopes in CD4 adjacent to the gp120-binding site. This analysis permits discrimination between mutations that probably cause localized conformational changes and those that alter residues likely to make direct contact with gp120 and with the mAb. Our results indicate that gp120 from two different strains of HIV binds to a larger region of the CD4 protein than previously described. The data has also been used to map the epitopes of mAb previously identified as anti-idiotype vaccine candidates. The results have important implications for the development of CD4-based therapies for AIDS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691226

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Metabolic stabilization of muscle nicotinic acetylcholine receptor by rapsyn.

Authors:  Z Z Wang; A Mathias; M Gautam; Z W Hall
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

2.  Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.

Authors:  E C Hsu; R E Dörig; F Sarangi; A Marcil; C Iorio; C D Richardson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Crystal structure of an HIV-binding recombinant fragment of human CD4.

Authors:  S E Ryu; P D Kwong; A Truneh; T G Porter; J Arthos; M Rosenberg; X P Dai; N H Xuong; R Axel; R W Sweet
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

5.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Mutations in the D strand of the human CD4 V1 domain affect CD4 interactions with the human immunodeficiency virus envelope glycoprotein gp120 and HLA class II antigens similarly.

Authors:  D Piatier-Tonneau; L N Gastinel; G Moussy; B Bénichou; F Amblard; P Vaigot; C Auffray
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

7.  Selection of an avian retrovirus mutant with extended receptor usage.

Authors:  R A Taplitz; J M Coffin
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

8.  Construction of a binding site for human immunodeficiency virus type 1 gp120 in rat CD4.

Authors:  G A Schockmel; C Somoza; S J Davis; A F Williams; D Healey
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

9.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.

Authors:  K A Page; S M Stearns; D R Littman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

10.  Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes.

Authors:  S Chen; R A Chrusciel; H Nakanishi; A Raktabutr; M E Johnson; A Sato; D Weiner; J Hoxie; H U Saragovi; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.